Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News AIM ImmunoTech Inc AIM

Healthcare Biotechnology
AIM ImmunoTech Inc. is an immuno-pharma company. It is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular ribonucleic acid (RNA) molecules, and Alferon N Injection (Interferon alfa). Its lead product is an investigational drug called... see more

Recent & Breaking News (NYSEAM:AIM)

Hemispherx Biopharma Introduces a Voluntary Stock Purchase Plan to Create Shareholder Value

GlobeNewswire February 3, 2016

Hemispherx Biopharma Europe N.V./S.A. : Orphan Medicine Designation and European Medicines Agency Public Opinion Summary Published by EMA Regarding Alferon N Injection® as a Treatment of Middle East Respiratory Syndrome (MERS)

GlobeNewswire January 20, 2016

Hemispherx Biopharma Announces Financial Results for the Nine Months Ended September 30, 2015

GlobeNewswire November 17, 2015

Hemispherx Biopharma Europe N.V./S.A. Receives Positive Opinion on Application for Orphan Designation by the European Medicines Agency for Alferon N Injection to Treat Patients With Middle East Respiratory Syndrome (MERS)

GlobeNewswire October 19, 2015

New Arrowhead Analyst Issues Updated Diligence and Valuation Report on Hemispherx Biopharma

GlobeNewswire September 30, 2015

Hemispherx Biopharma Receives the European Patent Office Grant of New Composition of Matter Patent Covering Ampligen(R) Formulations

GlobeNewswire September 28, 2015

Hemispherx Biopharma Reports Article by Senior Authors From Italian Ministry of Health and Related Agencies Suggesting Broad Applicability of Ampligen(R) to Multiple Sclerosis

GlobeNewswire September 23, 2015

Biotech Companies Clinical Trial & Preclinical Data Results Playing Important Developmental Role in Advanced Drug Treatment Therapies for Rare Conditions & Diseases

Accesswire September 21, 2015

Hemispherx Biopharma Research Team Identifies Characteristics of Chronic Fatigue Syndrome (CFS) Patients Potentially Predictive of Improved Response to Ampligen

GlobeNewswire September 21, 2015

Hemispherx Biopharma Announces Patient Assistance Program for Chronic Fatigue Syndrome Open Label Study

GlobeNewswire September 17, 2015

Hemispherx Biopharma Reports Low NK Cell Activity in Chronic Fatigue Syndrome (CFS) and Relationship to Disease Symptoms

GlobeNewswire September 15, 2015

Hemispherx Biopharma to Present at the 17th Annual Rodman & Renshaw Global Investment Conference in New York City September 8-10, 2015

GlobeNewswire September 2, 2015

Photo Release -- Hemispherx Biopharma Fully Aligns Executive Bonus Programs to Accelerate Product Revenue Opportunities and Market Entry

GlobeNewswire August 31, 2015

Photo Release -- Hemispherx Biopharma Posts Photographs of the Ampligen Facility in New Brunswick, New Jersey

GlobeNewswire August 27, 2015

Hemispherx Biopharma's Judgment Unanimously Affirmed Against Cato Capital

GlobeNewswire August 26, 2015

Photo Release -- Hemispherx Biopharma Hosts Stockholder Open House at Its Manufacturing and Research Development Center in New Jersey

GlobeNewswire August 26, 2015

Hemispherx Biopharma Enters Into Direct Supply Agreement With Gulf Coast Regional Blood Center to Supply Leukocytes to Manufacture Alferon N Injection(R)

GlobeNewswire August 24, 2015

Pomerantz Law Firm Announces Summary Notice of Pendency and Proposed Settlement of Hemispherx Biopharma, Inc. Class Action and Settlement Hearing - HEB

GlobeNewswire August 19, 2015

Hemispherx Biopharma Reminder Regarding Stockholder Open House at Manufacturing and Research Facility in New Jersey

GlobeNewswire August 19, 2015

Hemispherx Biopharma Extends Its Strategic Alliance With Armada Health Care for Alferon N Injection(R)

GlobeNewswire August 17, 2015